Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
What is the competitive landscape for BIOGEN IDEC, and what generic alternatives to BIOGEN IDEC drugs are available?
BIOGEN IDEC has two approved drugs.| Patents: | 15 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
dimethyl fumarate | Delayed-releaseCapsules | 120 mg and 240 mg | TECFIDERA | 3/27/2017 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,586,559 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | ► Subscribe | |||||||||||||||||||||||||||
| 5,760,202 | Process for the synthesis of 2'-O-substituted pyrimidines | ► Subscribe | |||||||||||||||||||||||||||
| 6,172,216 | Antisense modulation of BCL-X expression | ► Subscribe | |||||||||||||||||||||||||||
| 6,642,367 | Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | ► Subscribe | |||||||||||||||||||||||||||
| 6,222,025 | Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | ► Subscribe | |||||||||||||||||||||||||||
| 9,107,933 | Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III | ► Subscribe | |||||||||||||||||||||||||||
| 7,612,110 | Utilization of dialkylfumarates | ► Subscribe | |||||||||||||||||||||||||||
| 9,476,042 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | ► Subscribe | |||||||||||||||||||||||||||
| 7,915,310 | Utilization of dialkylfumarates | ► Subscribe | |||||||||||||||||||||||||||
| 5,861,493 | Process for the synthesis of 2'-O-substituted pyrimidines | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 261984 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 245096 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 655937 | ► Subscribe | |||||||||||||||||||||||||||
| Serbia | 49995 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 2002341548 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 105033 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1131465 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 3131222 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 222290 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 0586570 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 487 | Luxembourg | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140203 | ||||||||||||||||||||||||||
| 2014 00036 | Denmark | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130 | ||||||||||||||||||||||||||
| C/GB02/030 | United Kingdom | ► Subscribe | PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | ||||||||||||||||||||||||||
| C/GB01/008 | United Kingdom | ► Subscribe | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 | ||||||||||||||||||||||||||
| 2014024 | Lithuania | ► Subscribe | PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130 | ||||||||||||||||||||||||||
| 90038-5 | Sweden | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140203 | ||||||||||||||||||||||||||
| 90039-3 | Sweden | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130 | ||||||||||||||||||||||||||
| C/GB98/002 | United Kingdom | ► Subscribe | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 | ||||||||||||||||||||||||||
| 2014023 | Lithuania | ► Subscribe | PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130 | ||||||||||||||||||||||||||
| 2014 00035 | Denmark | ► Subscribe | PRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,716 others who get our Drug Patent Expiration Alerts:
